Simultaneous quantitation of delamanid (OPC-67683) and its eight metabolites in human plasma using UHPLC-MS/MS

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 1002, Issue , 2015, Pages 78-91

  Meng, Min ^a   Smith, Benjamin ^a   Johnston, Brad ^a   Carter, Spencer ^a   Brisson, Jerry ^a   Roth, Sharin E ^a  

^a Covance ^*  (United States)

Author keywords

Delamanid (code named OPC 67683); Human plasma; Selected reaction monitoring (SRM); Tuberculosis; Ultra high performance liquid chromatography and tandem mass spectrometry (UHPLC MS MS)

Indexed keywords

BIOMOLECULES; CHROMATOGRAPHY; EXTRACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOMERS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX ALGEBRA; METABOLITES; PLASMA (HUMAN); SPECTROMETRY;

DELAMANID (CODE-NAMED OPC-67683); HUMAN PLASMAS; SELECTED REACTION MONITORING; TANDEM MASS SPECTROMETRY; TUBERCULOSIS;

PLASMA STABILITY;

DELAMANID; DM 6704; DM 6705; DM 6706; DM 6717; DM 6718; DM 6720; DM 6721; DM 6722; DRUG METABOLITE; LOPINAVIR; RITONAVIR; UNCLASSIFIED DRUG; NITROIMIDAZOLE DERIVATIVE; OPC-67683; OXAZOLE DERIVATIVE; PLACEBO;

ACCURACY; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; ELECTROSPRAY; HUMAN; ISOMER; PRIORITY JOURNAL; QUALITY CONTROL; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; BLOOD; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIMIT OF DETECTION; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; VALIDATION STUDY;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOUBLE-BLIND METHOD; HUMANS; LIMIT OF DETECTION; NITROIMIDAZOLES; OXAZOLES; PLACEBOS; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY;

EID: 84940021216     PISSN: 15700232     EISSN: 1873376X     Source Type: Journal    
DOI: 10.1016/j.jchromb.2015.07.058     Document Type: Article

References (15)

1. WHO Tuberculosis, Fact Sheet Number 104 2010, WHO, Geneva, Switzerland.
2. WHO, Global Tuberculosis Report 2014, ISBN 978 92 4 156480 9,. http://apps.who.int/iris/bitstream/10665/137094/1/9789241564809_eng.pdf.
3. WHO Multidrug and Extensively Drug-resistant TB (M/XDR-TB): 2010 Global Report on Surveillance and Response 2010, WHO, Geneva, Switzerland.
4. Kaneko T., Cooper C., Mdluli K. Future Med. Chem. 2011, 3(11):1373.
5. Sasaki H., Haraguchi Y., Itotani M., et al. J. Med. Chem. 2006, 49(26):7854.
6. Matsumoto M., Hashizume H., Tomishige T., Kawasaki M., Tsubouchi H., Sasaki H., Shimokawa Y., Komatsu M. PLoS Med. 2006, 3(11):2131.
7. Diacon A.H., Dawson R., Hanekom M., Narunsky K., Venter A., Hittel N., Geiter L.J., Wells C.D., Paccaly A.J., Donald P.R. Int. J. Tuberc. Lung Dis. 2011, 15(7):949.
8. Gler M.T., Skripconoka V., Sanchez-Garavito E., Xiao H., et al. N. Engl. J. Med. 2012, 366(23):2151.
9. Skripconoka V., Danilovits M., Pehme L., Tomson T., Skenders G., Kummik T., Cirule A., Leimane V., Kurve A., Levina K., Geiter L.J., Manissero D., Wells C.D. Eur. Respir. J. 2012, 41(6):1393.
10. Kolyva A.S., Karakousis P.C. Old and new TB drugs: mechanisms of action and resistance. Understanding Tuberculosis-New Approaches to Fighting Against Drug Resistance 2012, Intech, ISBN 978-953-307-948-6 (Chapter 9). P.-J. Cardona (Ed.).
11. Hirao Y., Koga T., Koyama N., Shimokawa Y., Umehara K. Am. J. Anal. Chem. 2015, 6:98.
12. Guidance for Industry, Bioanalytical Method Validation, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine, 2001. Available at. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM368107.
13. Mallet C.R., Lu Z., Mazzeo J.R. Rapid Commun. Mass Spectrom. 2004, 15:141.
14. P. Bennett, K.C. Van Horne, Poster 6006, 2003 AAPS.
15. Meng M., Wang L., Voelker T., Reuschel S., Van Horne K.C., Bennett P.K. Bioanalysis 2013, 5(1):91.